Compare TUSK & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | ARCT |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 163.4M |
| IPO Year | 2016 | 2019 |
| Metric | TUSK | ARCT |
|---|---|---|
| Price | $3.12 | $15.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $24.11 |
| AVG Volume (30 Days) | 231.4K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | 20.00 |
| EPS | ★ 0.09 | N/A |
| Revenue | $44,292,000.00 | ★ $82,031,000.00 |
| Revenue This Year | $383.90 | N/A |
| Revenue Next Year | N/A | $12.77 |
| P/E Ratio | $35.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $5.50 |
| 52 Week High | $3.92 | $24.14 |
| Indicator | TUSK | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 85.81 |
| Support Level | $2.12 | $6.40 |
| Resistance Level | $3.49 | N/A |
| Average True Range (ATR) | 0.18 | 1.22 |
| MACD | -0.01 | 0.80 |
| Stochastic Oscillator | 35.71 | 89.51 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.